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The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some
of these therapies affect bone metabolism, resulting in osteoporosis. Aromatase inhibitors lower circulating oestrogen levels to almost
unrecordable levels in postmenopausal women, predisposing them to bone loss with an increase in fracture risk. Ongoing clinical trials
are favouring the use of the aromatase inhibitors over tamoxifen and this may advocate greater use of these drugs in the future.
Strategies for the identification and management of treatment-induced bone loss are currently being defined.
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The incidence of breast cancer is rising steadily and at present is
the most common cancer in women. New therapeutic options are
improving survival and this is exposing an increasing population
to the late complications of breast cancer and its treatment. In the
last few years, research has shown that breast cancer has important
implications for bone health. Of major concern is the development
of bone metastasis, but many breast cancer patients are at
increased risk for developing osteoporosis, which is also associated
with marked morbidity and mortality (Adachi et al, 2002;
Cummings and Melton, 2002; Hasserius et al, 2003; Marks et al,
2003).
The pathogenesis of osteoporosis is complicated with many
factors involved, although oestrogen deficiency is perhaps the
most important factor. The increasing use of chemotherapy in
young women leading to premature menopause, and the
introduction of aromatase inhibitors into the adjuvant setting
for postmenopausal women have improved outcome, but have
clinically important consequences on bone mineral density (BMD)
and fracture risk.
Bone mineral density is a surrogate marker of lifetime exposure
to oestrogen and therefore is a risk factor for developing breast
cancer (Cauley et al, 1996; Zhang et al, 1997). Consequently, newly
diagnosed breast cancer patients have a higher average BMD than
the normal age-matched population (van der Klift et al, 2003).
Despite this, it is becoming increasingly evident that breast
cancer and its treatment are associated with the development
of osteoporotic fracture. In a study by Kanis et al (1999), 1210
patients with breast cancer but no evidence of bone metastasis
were investigated. The incidence of vertebral fracture was 5.4% in
the newly diagnosed breast cancer patients compared with only
1.5% in age-matched women without breast cancer.
The reductions in circulating oestrogen levels that occur at the
menopause are associated with a rapid deterioration in bone mass
by as much as 3% per year for the first 5 years after the menopause
(Riggs et al, 1998). After the menopause, intrinsic production of
oestrogen from androgens largely occurs in nonovarian tissues
such as fat, muscle, skin and liver as a result of the activity of the
aromatase enzyme complex (Sluijmer et al, 1995). The resulting
low levels of circulating oestrogen help to prevent a more
exaggerated bone loss (Cummings et al, 1998a).
CAUSES OF ACCELERATED BONE LOSS IN BREAST
CANCER
There are many treatments for breast cancer that increase the risk
of osteoporosis; these are outlined below (Table 1).
Chemotherapy
Indirect effects The use of chemotherapy in premenopausal
patients commonly induces a sudden deterioration in oestrogen
production and often an early menopause. A study by Shapiro et al
(2001) investigated 49 premenopausal stage 1 and 2 breast cancer
patients treated with adjuvant chemotherapy. After 1 year, 35
(71%) patients were found to have ovarian failure and these
patients lost on average 4.0% (P¼0.0001) of the lumber spine
BMD after just 6 months. This rate of bone loss was maintained at
12 months with a further 3.7% (P¼0.0001) of bone loss.
Direct effects Studies on rat skeletons after the administration of
methotrexate suggest that chemotherapy may have a direct impact
on bone by inhibiting proliferation. After treatment, bone
histomorphometry showed a significant reduction in bone volume,
strength and mineralisation surface compared with controls
(Po0.05) (Wheeler et al, 1995).
A study by Greep et al (2003) assessed postmenopausal patients
who are not susceptible to the ovarian suppression caused by
chemotherapy. The changes observed in BMD suggested a possible
direct effect of chemotherapy. Although no significant change in
BMD T-score (based on peak bone mass) was seen, the Z-score
(age-adjusted difference from the mean) did fall more rapidly
than in control patients. The average change in Z-score for chemo-
therapy patients was  0.65 (P¼0.0002) at the total hip and  0.60
(P¼0.05) at the lumbar spine.
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on bone metabolism, particularly bone formation, but overall,
premature ovarian failure is the major cause of chemotherapy-
induced bone loss.
Tamoxifen
Tamoxifen has a complicated mechanism of action with potent
antioestrogenic effects on the breast, but also partial oestrogen
agonist effects on bone, uterus and lipids. The partial agonist effect
appears to have varying impacts on bone metabolism depending
on the intrinsic circulating levels of oestrogen. Postmenopausal
women receiving tamoxifen therefore may be protected from the
development of osteoporosis, due to the mild oestrogen agonist
action. Love et al (1992) conducted a placebo-controlled trial
investigating 140 postmenopausal women with breast cancer
receiving tamoxifen. After 2 years, BMD of the lumbar spine
increased by 0.61% per year in the tamoxifen group (P¼0.04) and
declined by 1.0% per year in the placebo group (Po0.001). A
similar study by Kristensen et al (1994) also showed that
postmenopausal women on tamoxifen therapy had a significantly
higher BMD than placebo-treated patients (Po0.0074).
Premenopausal women, however, are rendered relatively oestro-
gen deficient by tamoxifen and as a result may be more prone
to osteoporosis in later life. A study by Powles et al (1996)
investigated 125 premenopausal women and found that they lost
on average 1.44% of their lumbar spine BMD every year on
tamoxifen treatment. Placebo-treated patients, however, showed a
modest gain in their BMD (Po0.001) (Figure 1).
Ovarian ablation/suppression
Surgical Surgical removal of the ovaries is an effective therapy
for premenopausal patients with breast cancer (Ingle et al, 1986;
Table 1 Agents causing bone loss in breast cancer patients
Treatment Study
Patient
numbers Subjects Outcome
Chemotherapy
Indirect Shapiro et al (2001) 49 Premenopausal women k Spine BMD by 4% in 6 months
P¼0.0001
Vehmanen et al (2001) 148 Premenopausal women k Spine BMD by 7.5% in 36 months
P¼0.0001
Direct Wheeler et al (1995) 69 Rats k Bone volume, k mineralising surface, m osteoclast surface
Po0.05
Greep et al (2003) 130 Postmenopausal women No significant change in T-score, significant changes in Z-score at
lumbar spine, BMD k 0.6
P¼0.05
Tamoxifen
Powles et al (1996) 125 Premenopausal women k Spine BMD by 1.44% in 12 months
Po0.001 (vs placebo)
Ovarian ablation
Drug induced Leather et al (1993) 19 Premenopausal women k Spine BMD by 4.8% in 6 months
Po0.001
Surgical Hashimoto et al (1995) 244 Premenopausal women k Spine BMD by 10.7% in 12 months
Aromatase inhibitors
Anastrozole Eastell et al (2002) 308 Postmenopausal women k Spine BMD by 2.6% in 12 months
Letrozole Goss et al (2003) 5187 Postmenopausal women m Osteoporosis in letrozole group vs placebo, 5.8 vs 4.5%
P¼0.07
Exemestane Coombes et al (2004) 4742 Postmenopausal women m Osteoporosis in exemestane group vs tamoxifen group, 7.4 vs 5.7%
P¼0.05
Lonning et al (2004) 147 Postmenopausal women k Spine BMD at an annual rate of 2.17%
BMD¼bone mineral density.
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Figure 1 Changes in BMD of (A) the hip and (B) the spine in
premenopausal women on tamoxifen or placebo. Reproduced with
permission from Powles et al (1996).
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procedure is associated with a rapid decline in oestrogen and bone
strength. Hashimoto et al (1995) investigated 244 women who were
having regular menstrual cycles up until the point of surgical
oophorectomy. After 1 year, the mean BMD declined by 10.7%.
Drug induced The gonadorelin analogue, goserelin, is licensed
for the treatment of premenopausal patients with advanced breast
cancer and is increasingly used in the adjuvant setting. Goserelin
induces ovarian failure followed by a rapid decline in circulating
oestrogen. As a consequence, BMD can deteriorate by as much as
4.8% within the lumbar spine after just 6 months (Leather et al,
1993).
Aromatase inhibitors
Aromatase inhibitors are potent inhibitors of oestrogen produc-
tion and at present are commonly used in patients with metastatic
disease and in some early breast cancer patients who are
unsuitable for treatment with tamoxifen. Two types of aromatase
inhibitor are currently available, which have different mecha-
nisms of action. The nonsteroidal agents (anastrozole, letrozole
and aminoglutethimide) are reversible inhibitors, while steroidal
agents (exemestane and formestane) are irreversible inactivators of
the aromatase enzyme. The third-generation aromatase inhibitors
anastrozole, letrozole and exemestane are the most powerful drugs
available resulting in approximately 96–99% enzyme inhibition
(Dowsett et al, 1995; Geisler et al, 1996, 1998). This marked
reduction in oestradiol would be expected to have profound effects
on bone physiology. The decision on which drugs to use in the
future will depend upon the clarity of the results of trials in
metastatic disease and adjuvant therapy, as well as ‘head to head’
comparison of the agents (Cummings, 2002).
Anastrozole Anastrozole has shown clear advantages over
megestrol acetate as second-line therapy for advanced breast
cancer and to be at least as good as tamoxifen for first-line therapy
(Buzdar et al, 1998; Nabholtz et al, 2000). It is also being used
increasingly in the adjuvant setting. Preliminary results from the
Arimidex, Tamoxifen Alone or in Combination (ATAC) trial have
been published (ATAC, 2002). The study included over 9000
postmenopausal patients who had completed primary therapy for
breast cancer and who were eligible for endocrine therapy. Patients
were randomised equally between anastrozole, tamoxifen or a
combination of both. Results published after a median follow-up
of 33.3 months found that anastrozole improved disease-free
survival, time to disease recurrence and incidence of contralateral
primary breast cancer compared with both tamoxifen and the
combination of drugs. Updated results confirmed these early
observations (Baum et al, 2003).
From the perspective of adverse events, anastrozole was better
tolerated except for the occurrence of musculoskeletal side effects
and the incidence of fractures, mainly of the spine and wrist. After
a median follow-up of 37 months, the incidence of all fractures was
7.1% in the anastrozole group and 4.4% in the tamoxifen group
(Po0.0001) (ATAC, 2002) (Table 2). Although the fracture rate
in anastrozole-treated women appeared to plateau after around 18
months, with no progressive increase in fracture risk (Table 3), the
increased fracture risk seen in the anastrozole patients still
remained significant (Po0.0001) (Howell, 2003; Locker and
Eastell, 2003). The fracture rate per 1000 women years was 21.55
with anastrozole compared with 13.44 with tamoxifen. A popula-
tion of healthy women of similar median age would be expected to
have a fracture rate per 1000 women years of 19.10 (Writing Group
for the Women’s Health Initiative Investigators, 2002).
The bone subprotocol of the ATAC trial investigated 308
patients and assessed them for any changes in BMD and bone
turnover markers (Eastell et al, 2002). After 2 years treatment with
anastrozole, the BMD had fallen on average by 4.0% in the lumbar
spine and 3.2% in the hip. There was also a 15% increase in the
bone resorption marker N-terminal telopeptide (NTX) and a 21%
increase in bone alkaline phosphatase, a bone formation marker.
At this early stage, this is clear evidence that anastrozole reduces
BMD in postmenopausal women and does not have the bone
protective effects of tamoxifen.
Letrozole Letrozole is superior to megestrol acetate in the
treatment of advanced breast cancer and is clearly superior to
tamoxifen as first-line therapy in high-risk or advanced disease
(Buzdar et al, 2001; Ellis et al, 2001; Mouridsen et al, 2001).
Recently, Goss et al (2003) investigated the role of letrozole after
treatment with 5 years of adjuvant tamoxifen. Patients with breast
cancer (n¼5187) were randomised to further treatment with
letrozole or placebo after the completion of 5 years of tamoxifen
therapy. After a median follow-up of just 2.4 years, the estimated
4-year disease-free survival was 93% in the letrozole group and
87% in the placebo group (Po0.001). Only 61 (2.4%) patients
treated with letrozole developed recurrent disease compared to
106 (4.1%) in the placebo group. Unfortunately, as the study was
discontinued early, the long-term effects of letrozole are not
yet known. However, at this early stage, more diagnoses of
osteoporosis have been made in the letrozole group compared with
the placebo group, at 5.8 and 4.5% respectively (P¼0.07),
suggesting that, like anastrozole, letrozole increases bone loss
and fracture risk (Goss et al, 2003). The first results of a specific
bone subprotocol evaluating changes in BMD and bone markers
were presented by Perez et al (2004). Letrozole patients (n¼122)
experienced a significant decrease in total hip BMD compared with
placebo (n¼104) from baseline ( 3.6 vs  0.71%, P¼0.044) and a
significant decrease in lumbar spine BMD ( 0.35 vs  0.7%,
P¼0.008) at 24 months. Letrozole also increased the bone
resorption marker NTX. In addition, more women receiving
letrozole became osteoporotic at the L2–4 spine by BMD criteria
Table 2 Incidence of fracture in ATAC trial (adapted with permission
from ATAC Trialists’ Group, 2002)
Anastrozole (n¼3092) Tamoxifen (n¼3094)
Total fractures 183 (5.9%) 115 (3.7%)
Spine fractures 23 (0.7%) 10 (0.3%)
Wrist fractures 36 (1.2%) 25 (0.8%)
Hip fractures 11 (0.4%) 13 (0.4%)
ATAC trial¼Arimidex, Tamoxifen Alone or in Combination trial.
Table 3 6-monthly fracture rates per 100 patients at a median follow-up
of 37 months in the ATAC trial (Howell, 2003; Locker and Eastell, 2003)
6-monthly fracture rates/100
patients
Anastrozole/
tamoxifen 6-month
hazard ratio
Time
(months)
Anastrozole
(n¼3092)
Tamoxifen
(n¼3093)
6 1.11 0.99 1.14
12 0.93 0.58 1.61
18 1.36 0.69 1.98
24 1.57 0.61 2.57
30 1.39 0.96 1.45
36 1.09 0.66 1.66
42 1.50 1.37 1.09
48 1.07 0.80 1.34
ATAC trial¼Arimidex, Tamoxifen Alone or in Combination trial.
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significant (3.3 vs 0%).
Small short-term studies have shown that letrozole has an
impact on markers of bone turnover. Harper-Wynne et al (2001)
found that C-terminal telopeptide (CTX), a marker of bone
resorption, increased from a mean of 2300 to 2828 after 3 months
of letrozole therapy (Po0.005). Over a 12-week period, Goss et al
(2002) found that letrozole therapy reduced the bone formation
marker, bone-specific alkaline phosphatase (BAP), by 20.1% while
the bone resorption marker CTX increased by 11.4%. The study
also investigated the impact of exemestane on bone turnover as
discussed below.
The ZOFAST study is presently recruiting postmenopausal
breast cancer patients with normal bone density. Patients are
treated with letrozole and randomised to either immediate
intravenous zoledronate or to a delayed phase of treatment based
on changes in BMD. Subsequent DXA scans will determine if
zoledronate can prevent bone loss in these patients and when they
should be considered for treatment with a bisphosphonate. Initial
results from the study were reported at the end of 2004, with 587
patients having baseline BMD data (Brufsky et al, 2004). At that
point, there was a 3.33% difference in lumbar spine BMD in favour
of upfront treatment with zoledronate and a 2.42% difference in
favour of upfront treatment with total hip BMD.
Exemestane Exemestane is a steroidal aromatase inhibitor, which
is also superior to megestrol acetate (Kaufmann et al, 2000).
There are recent data indicating superior efficacy to tamoxifen
(Paridaens et al, 2004) and the drug retains activity after treatment
with nonsteroidal aromatase inhibitors. Exemestane is also being
evaluated in the adjuvant setting. Results from direct comparison
with tamoxifen are not expected for some time. However, the first
data from a trial testing the sequence of tamoxifen for 2–3 years
followed by exemestane for 2–3 years vs standard treatment with
5 years tamoxifen have recently been presented (Coombes et al,
2004). After a median follow-up of 30.6 months, significant
reductions in first cancer-related events, disease-free survival and
contralateral breast cancer were seen in the exemestane group.
There was a nonsignificant increase in osteoporosis for both
treatment groups, with 171 (7.4%) exemestane-treated patients and
134 (5.7%) tamoxifen-treated patients diagnosed with osteoporosis
(P¼0.05 exemestane vs tamoxifen). Similarly, there was a
nonsignificant increase in reported fractures, with a trend towards
increased fracture rate seen in the exemestane group (exemestane
3.1% vs tamoxifen 2.3%; P¼0.08).
The first data from the bone subprotocol of 206 patients have
recently become available (Coleman et al, 2004). Patients who
switched from tamoxifen to exemestane lost 2.7% lumbar spine
BMD after 6 months and 3.2% after 12 months. For patients who
continued on tamoxifen, the mean rates of bone loss were 0.2 and
0.2% at the spine after 6 and 12 months. These differences were
significant at both time points (Po0.0001). The rapid decline in
BMD after 6 months may be due to the withdrawal of tamoxifen as
much as the introduction of exemestane. Further data from
measurements after 2 years will help to evaluate subsequent bone
loss.
A study to investigate the effect of exemestane and letrozole on
markers of bone turnover in postmenopausal women was recently
updated at the San Antonio Breast Cancer Symposium (Goss et al,
2002). Exemestane was associated with a reduction in bone
resorption markers compared with letrozole. Urinary CTX
increased by 11.4% in patients treated with letrozole, but in the
exemestane group it declined by 23.4%. This suggested that
exemestane may have a bone-preserving action that is not seen
with other aromatase inhibitors. However, the trial only involved
60 patients and follow-up was just 12 weeks. In contrast, a small
substudy by Martinetti et al (2003) found that exemestane
increased levels of bone turnover markers. A total of 23
postmenopausal patients with or without bone metastasis from
metastatic breast cancer were randomised to treatment with
exemestane, and samples for BAP, CTX and insulin-like growth
factor were taken after 8 weeks. In the population as a whole,
exemestane resulted in significant increases in both BAP and CTX
(Po0.01).
Very recently, the preliminary results of a study comparing
adjuvant exemestane with placebo in low-risk breast cancer
patients were presented by Lonning et al (2004). At 24 months,
CTX had increased from baseline by 35% with exemestane and
fallen by 5% on placebo. Bone formation markers also rose,
with changes in a variety of bone formation markers that were
somewhat greater than might have been expected through normal
bone cell coupling. The authors suggested that this reflected the
anabolic action of the main metabolite of exemestane, 17-hydro
exemestane. In terms of BMD, the same group reported an annual
bone loss of 2.17 and 2.72% at the spine and hip, respectively
(Lonning et al, 2004). Surprisingly, bone loss in the placebo group
was greater than expected at 1.84 and 1.48% at the spine and hip,
respectively, and so there was no significant difference between
the two groups, although a clear trend for more rapid bone loss
on exemestane was evident. None of the women were taking
calcium or vitamin D supplements, and in Scandinavia at a median
age of over 60 years a high proportion would be expected to
be vitamin D deficient. This may have confounded the results
somewhat. Overall, despite the weak androgenic effects of exeme-
stane, it is likely that the profound suppression of circulating
oestrogens caused by the potent inhibition of aromatase will over-
ride this and, as with the nonsteroidal aromatase inhibitors,
promote accelerated bone loss.
TREATMENT
Vitamin supplements
Calcium and vitamin D supplements are of benefit in preventing
osteoporotic fracture in elderly women and may slow the
development of osteoporosis in the over 65 years age group (Goss
et al, 2003; Martinetti et al, 2003). These supplements have
relatively few side effects and should be taken on a routine basis
both alone and in combination with antiresorptive therapy.
Antiresorptives
Bisphosphonates The bisphosphonates are potent inhibitors of
osteoclast function and can improve BMD of the lumbar spine by
5–10% in 2 years. This degree of improvement correlates with a
reduction in fracture risk by approximately 50% (Eastell, 1998).
Bisphosphonates of proven clinical benefit in treating osteoporosis
by reducing fracture rates include alendronate (Liberman et al,
1995; Black et al, 1996, 2000; Cummings et al, 1998b) and
risedronate (Harris et al, 1999; Reginster et al, 2000).
Presently available intravenous bisphosphonates include pami-
dronate, zoledronic acid and ibandronate. Zoledronic acid can be
given annually at a dose of 4mg and is as potent as daily oral
preparations (Reid et al, 2002). In the treatment of cancer-induced
bone loss, several studies have shown the benefit of using
bisphosphonates to preserve BMD and presumably therefore the
prevention of osteoporosis. Delmas et al (1997) reported on the
use of risedronate to prevent bone loss associated with
chemotherapy-induced early menopause.
Powles et al (1998) recruited more than 300 women with
primary operable breast cancer from the adjuvant clodronate trial.
After 2 years, patients treated with placebo lost on average 1.88%
of their lumbar spine BMD. Clodronate-treated patients however
lost just 0.16% (P¼0.04). Gnant et al (2002) are presently
investigating the effect of intravenous zoledronic acid therapy on
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tamoxifen or goserelin and anastrozole. Early results from this
study show a significant benefit in favour of zoledronic acid for
BMD of the lumbar spine and hip (Po0.0001) for the patients
treated with zoledronic acid.
SUMMARY
At the time of diagnosis, breast cancer patients have a somewhat
higher mean BMD compared with age-matched controls. Despite
this, there is evidence that patients with breast cancer are at a
greater risk for developing osteoporosis. Future trends in the
treatment of breast cancer are likely to advocate the use of
aromatase inhibitors, which will exacerbate this problem. One way
to approach this would be to screen all breast cancer patients with
regular DXA scans, and treat them with bisphosphonates as
appropriate. However, this would put a major strain on resources
and is unlikely to be cost effective.
Consideration of risk factors for osteoporosis and fracture may
help identify patients who would benefit most from investigations
into their bone density. Clear evidence-based guidelines would
help physicians identify which patients to investigate and provide
effective treatment, and may open the door to easier access to
DXA. The American Society of Clinical Oncology (ASCO) (Hillner
et al, 2003) recognised this problem and recently published
guidelines to help identify patients at high risk by a series of
criteria and suggest treatment depending upon results of DXA
scans of the hip or spine.
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